Johnson & Johnson's Rybrevant Plus Chemotherapy Delivers Longest Reported Median Overall Survival in EGFR Exon 20 Insertion Mutation-positive Lung Cancer
September 15, 2026
September 15, 2026
RARITAN, New Jersey, Sept. 15 -- Johnson and Johnson Innovative Medicine issued the following news release:
* * *
Johnson & Johnson's RYBREVANT(R) (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer
RYBREVANT plus chemotherapy demonstrates durable benefit with a differentiated approach that dual-targets EGFR and MET
Results mark significant progr . . .
* * *
Johnson & Johnson's RYBREVANT(R) (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer
RYBREVANT plus chemotherapy demonstrates durable benefit with a differentiated approach that dual-targets EGFR and MET
Results mark significant progr . . .